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Abstract
Objectives To determine the relationship between lung
function impairment and quantitative computed tomogra-
phy (CT) measurements of air trapping and emphysema in
a population of current and former heavy smokers with and
without airflow limitation.
Methods In 248 subjects (50 normal smokers; 50 mild
obstruction; 50 moderate obstruction; 50 severe obstruction;
48 very severe obstruction) CT emphysema and CT air
trapping were quantified on paired inspiratory and end-
expiratory CT examinations using several available quantifi-
cation methods. CT measurements were related to lung
function (FEV1,F E V 1/FVC, RV/TLC, Kco) by univariate
and multivariate linear regression analysis.
Results Quantitative CT measurements of emphysema and
air trapping were strongly correlated to airflow limitation
(univariate r-squared up to 0.72, p<0.001). In multivariate
analysis, the combination of CT emphysema and CT air
trapping explained 68-83% of the variability in airflow
limitation in subjects covering the total range of airflow
limitation (p<0.001).
Conclusions The combination of quantitative CT air trap-
ping and emphysema measurements is strongly associated
with lung function impairment in current and former heavy
smokers with a wide range of airflow limitation.
Key Points
￿ CT helps to automatically assess lung disease in heavy
smokers
￿ CT quantitatively measures emphysema and small airways
disease in heavy smokers
￿ CT air trapping and CT emphysema are associated with
lung function impairment
Keywords Pulmonary emphysema.Respiratory
bronchioles.Quantitative computed tomography.
Pulmonary function test.Chronic obstructive pulmonary
disease
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Chronic Obstructive Pulmonary Disease (COPD) is
characterized by chronic airflow limitation, and its
severity is graded according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria [1].
The airflow limitation in COPD patients is caused by
parenchymal destruction (i.e. emphysema) and small
airways disease with airway inflammation and airway
remodeling, which leads to expiratory airway obstruction
and air trapping [2, 3]. Emphysema has been quantified in
vivo by computed tomography (CT) for decades [4], but in
vivo detection of small airways disease has been difficult
since these small airways (diameter <2 mm) can not be
visualized directly with current CT techniques. Nakano et
al suggested that measurements of large airway wall
thickening can be used as an indirect sign of small airways
disease [5]. However, quantification of airway wall
dimensions remains technically challenging. Alternatively,
air trapping on end-expiratory CT may be easier to
quantify, and is possibly a more direct measurement of
small airways dysfunction. For this, the main challenge is
to separate air trapping due to small airways disease from
air that remains in emphysematous spaces after expiration
[6].
Separate quantification of air trapping and emphysema is
relevant for two reasons. First, COPD is a disease with a
wide heterogeneity [7–10], and COPD phenotyping may be
possible when quantitative CT is combined with clinical
and physiological characteristics. Second, quantitative CT
of COPD components might gain a role in (early) diagnosis
of the disease; a risk estimate for COPD may be calculated
from CT data, providing additional information in subjects
who undergo CT. This strategy may be especially interest-
ing in lung cancer screening, where large numbers of CT
examinations are obtained in heavy smokers. Here, CT may
reveal ‘hidden’ disease in undiagnosed COPD patients, and
might reveal disease in patients with lung function still
within the normal range [11].
The purpose of this study was to determine the
relationship between lung function impairment and quanti-
tative CT measures of air trapping and emphysema in
heavy smokers with and without COPD.
Methods
To study COPD in a lung cancer screening trial [12],
pulmonary function tests (PFT) and an expiratory CT data
acquisition had previously been added to the screening
protocol in our center. In the present study, we automati-
cally assessed emphysema and air trapping in CT examina-
tions obtained in this lung cancer screening population.
Since limited subjects with severe airflow limitation were
present in the screening trial, we added clinical subjects to
be able to study the total range of COPD.
This retrospective study was approved by our institu-
tional ethics board; written informed consent was obtained
in the screening trial participants, and waived for the
clinical subjects.
Subjects
Within the lung cancer screening trial participants, random
samples of 50 subjects were drawn for each GOLD stage
[1], resulting in 50 GOLD 1, 50 GOLD 2 and 24 GOLD 3
subjects. The clinical subjects underwent outpatient inspi-
ratory and expiratory CT and PFT examination for evalu-
ation of COPD and/or lung transplantation screening. Cases
with GOLD 3 of GOLD 4 were selected. No CTs contained
major breathing artifacts, and scans with signs of acute
pneumonia were excluded. The GOLD 3 study population
was extended to 50 subjects with a random sample of
clinical subjects. The GOLD 4 group consisted of all
available clinical subjects (N=48).
Additionally, we selected a group of normal smokers
from the screening trial participants. We defined ‘normal
smoker’ as two normal lung function tests with at least a
two-year interval, plus a slow rate of lung function decline.
Normal lung function was defined as FEV1 (forced
expiratory volume in one second) >80% predicted and
FEV1/FVC (forced expiratory volume in one second /
forced vital capacity) >70%. A slow rate of decline was
defined as an FEV1 decline less than 29 ml per year [13].
Seventy subjects fulfilled these criteria, of whom 50 were
randomly selected.
Pulmonary function testing
Spirometry, body plethysmography and diffusion capacity
testing was obtained according to ERS guidelines [14]. PFT
was performed with ZAN, Oberthulba, Germany. Spirom-
etry was obtained in all subjects and included forced
expiratory volume in 1 second (FEV1), forced vital capacity
(FVC) and the ratio of forced expiratory volume in 1
second over forced vital capacity (FEV1/FVC). Data on
bronchodilator use on the day of examination was not
available, and reversibility with bronchodilation was not
assessed. Due to restrictions in testing capacity during
screening rounds, extensive pulmonary function testing was
only performed in a subgroup of subjects. For our study
population, RV/TLC (ratio of residual volume to total lung
capacity) was available in 121 subjects, and Kco (ratio of
diffusion capacity over alveolar volume) in 103 subjects.
For lung cancer screening subjects, PFT was performed on
the same day as CT. For clinical subjects, the PFT
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1 day, interquartile range 0–4 days).
Computed tomography
Volumetric inspiratory CT and volumetric end-expiratory
CT after standardized breathing instructions were obtained
between July 2007 and September 2008. All CT examina-
tions were performed without intravenous contrast medium,
using 16 slice CT (Brilliance 16P, Philips Medical Systems,
Cleveland, OH) and 0.75 mm collimation. Settings were
adjusted to body weight: 120 kVp (≤80 kg) or 140 kVp
(>80 kg), both with 30 mAs, for inspiratory CT, and 90 kVp
(≤80 kg) or 120 kVp (>80 kg), both with 20 mAs, for
expiratoryCT.Asmoothreconstructionfilter(Bfilter,Philips,
Cleveland, OH ) was used, according to the protocol. Images
with slice thickness of 1.0 mm at 0.7 mm increment were
reconstructed from lung bases to lung apices.
The clinically evaluated patients that were added to the
screening population, underwent volumetric inspiratory CT
and volumetric end-expiratory CTafter standardized breath-
ing instructions between October 2003 and May 2010. CT
was performed without any intravenous contrast medium.
These CT examinations were acquired on various gener-
ations of CT equipment from the same vendor (Philips
Medical Systems, Cleveland, OH) with 16x0.75 mm
collimation on Brilliance 16P (N=16) and Mx8000 IDT
(N=12), 40x0.625 mm collimation on Brilliance 40 (N=8),
64x0.625 mm collimation on Brilliance 64 (N=32) or
128x0.625 mm collimation on Brilliance iCT (N=6).
Exposure settings were: 100kVp or 120kVp, both with
130mAs, for inspiratory CT, and 80-120kVp with 10-
30mAs for expiratory CT. A sharp reconstruction filter (C
kernel, Philips) was used, according to the clinical protocol.
Images with slice-thickness of either 0.9 or 1.0 mm at 0.45
or 0.7 mm slice-spacing were reconstructed from lung bases
to lung apices.
Emphysema and air trapping quantification
The lung parenchyma on inspiratory and expiratory CT data
sets was automatically segmented [15]. Additionally, lung
segmentation was checked visually, and those with major
errors (see Appendix 1) were excluded. Subjects that were
excluded were replaced by another random subject with a
corresponding GOLD stage (N=16). A noise reduction
filter [16] was applied to decrease the influence of noise on
the quantitative CT measurements.
The extent of emphysema was assessed by two widely
used quantitative CT measures:
1) The percentage of lung voxels below -950HU in
inspiration (IN−950)[ 17, 18].
2) The HU value at the 15th percentile of the attenuation
distribution histogram in inspiration (Perc15)[ 19].
The extent of air trapping was quantified by four
different methods:
1) The percentage of lung voxels below -850HU in
expiration (EXP−850)[ 20, 21].
2) The percentage of lung voxels between -850HU and -
910HUinexpiration(EXP-850 to −910). To correct for air in
emphysematous areas, method 1 was adjusted by exclud-
ing the voxels below -910HU, based on reference [22].
3) T h ec h a n g ei nr e l a t i v el u n gv o l u m ew i t ha t t e n u a t i o n
values from -860HU to -950HU (RVC-860 to −950)
between paired inspiratory and expiratory examinations
[6]. Practically, the RVC860-950 is calculated using the
formula: expiratory relative lung volume -860 to -950HU -
inspiratory relative lung volume -860 to -950HU.. In this,
the relative lung volume-860 to -950HU is defined as the
volume of voxels with attenuation values between −860
to -950HU divided by the volume of voxels with
attenuation values above -950HU (i.e. limited lung
volume, without emphysema) [6].
4) The expiration to inspiration ratio of mean lung density
(E/I-ratioMLD)[ 23–25].
Data analysis
CTmeasurementswerecomparedbetweenthefivegroups(i.e.
normal smokers and the four COPD stages) with analysis of
covariance (ANCOVA),with age, heightand sex as covariates.
Univariate and multivariate linear regression analysis were
performed to evaluate the relationship between lung function
parameters (dependent variables) and the CT measurements
(independentvariables).MultivariateanalysisincorporatedCT
emphysema (2 methods) and CT air trapping (4 methods),
while age,sex and height wereintroducedascorrectionfactors
for PFT. In order to meet linear regression requirements, we
used absolute values instead of the ‘percentage of predicted
value’,asthelatteroftenelicitsaheteroscedasticdistributionof
the residuals to one side [26]. Furthermore, multicollinearity
and the distribution of residuals was assessed for all models;
FEV1 and IN−950 were log-transformed (logFEV1 and
logIN−950) as to obtain a normal distribution, and warrant
symmetrical variance of the errors around zero (i.e. homo-
scedasticicy). Linear regression analyses were performed in
the total cohort of 248 subjects, as well as in the 174
screening trial participants separately.
All statistical analyses were performed using SPSS
software v15.0 (SPSS Inc, Chicago, Illinois, USA). A p-
value below 0.05 was considered statistical significant.
Continuous data are given as mean±SD, unless indicated
otherwise.
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Study population characteristics
The majority were male and the average age was around
60 years, except for the subjects in the GOLD 4 group who
were younger and more often female (Table 1). CT
emphysema and CT air trapping results were worse in the
COPD cases when compared to the smokers with normal
lung function, and the results worsened in the subsequent
COPD stages. Differences were significant except for IN−950
between normal smokers to GOLD2, Perc15 between
GOLD1 and GOLD2, EXP-850 to −910 and E/I-ratioMLD
between normal smokers and GOLD1, RVC-860 to −950
between normal smokers and GOLD2, and EXP-850 to −910
between GOLD3 and GOLD4.
Univariate regression analysis
Quantitative CT measurements showed moderate to strong
association with lung function parameters of airflow
limitation (R-squared values ranging from 0.25 to 0.72, p
<0.001 (Table 2, Fig. 1). CT emphysema measurements
were better correlated to Kco compared to RV/TLC. Also,
CT air trapping measurements were better correlated to RV/
Table 1 Patient characteristics, pulmonary function and quantitative CT measurements
Controls (n=50) GOLD1 (n=50) GOLD2 (n=50) GOLD3 (n=50) GOLD4 (n=48)
Male, n (%) 50 (100) 48 (96) 49 (98) 37 (74) 16 (33)
Age (years) 62.8±5.8 62.6±4.8 62.8±5.5 62.4±11 55.5±7.3
Pulmonary Function
Days between PFT and CT, median [P25 – P75] 0 [−]0 [ −]0 [ −]0 [ 0 –3] 1 [0–2]
FEV1 (L) 3.58±0.55 3.18±0.52 2.28±0.46 1.26±0.31 0.62±0.20
FEV1 (%predicted) 105.4±11.5 94.8±9.1 68.9±9.3 41.2±5.7 21.7±5.1
FEV1/FVC (%) 75.6±3.9 65.3±4.1 60.3±7.2 42.2±7.6 31.8±9.1
RV/TLC (%)
a 34.6±6.7 35.7±7.4 47.0±9.2 56.8±7.0 66.0±8.2
Kco (mmol/min/kPa/L)
b 1.32±0.23 1.12±0.26 1.20±0.30 0.88±0.32 0.72±0.22
CT Emphysema
c
IN−950 (%) 1.0±0.8 2.1±1.7
* 3.4±5.2
*† 11.6±10.0 27.9±14.3
Perc15 (HU) −906±20 −919±12 −920±19
† −938±21 −960±22
CT Air trapping
c
EX−850 (%) 11.3±9.6 16.5±14.4 25.9±17.9 50.0±16.8 70.0±12.8
EX-850to-910 (%) 9.9±8.6 13.8±11.0
* 20.9±13.3 31.4±9.9 25.6±6.8
‡
RVC-860to-950 (%) −54.2±18.3 −60.0±13.8 −49.2±16.2
* −23.4±13.1 −6.8±6.8
E/I-ratioMLD (%) 84.5±4.2 84.8±4.6
* 88.4±4.5 93.8±4.3 97.5±1.8
a121 subjects (n=31, 20, 14, 23, 33, respectively) with bodyplethysmography measurements;
b 103 subjects (n=30, 20, 15, 20, 18, respectively)
with diffusion capacity measurements;
c All categories are significantly different (p-value between <0.05 and <0.001), except when stated
otherwise;
* no significant difference compared to controls;
† no significant difference compared to GOLD1;
‡ no significant difference compared
to GOLD3; IQR Interquartile range; IN−950 =emphysema score below -950HU in inspiratory scan; Perc15 =emphysema score as 15
th percentile of
attenuation distribution curve in inspiratory scan; EXP−850 =air trapping score below -850HU in expiratory scan; EXP-850to-910 =air trapping score
between -850HU and -910HU in expiratory scan; RVC-860to-950 =air trapping score as relative volume change between -860HU and -950HU; E/I-
ratioMLD =expiration to inspiration ratio of mean lung density
Table 2 Results of univariate linear regression analysis for quantita-
tive CT measurements of emphysema and air trapping and pulmonary
function tests
logFEV1 FEV1/FVC RV/TLC
a Kco
b
CT Emphysema
logIN−950 0.53 0.61 0.42 0.52
Perc15 0.44 0.53 0.35 0.45
CT Air trapping
EX−850 0.69 0.72 0.63 0.44
EX-850to-910 0.25 0.33 0.31 0.18
RVC-860to-950 0.66 0.58 0.51 0.27
E/I-ratioMLD 0.60 0.60 0.56 0.31
Data given are r-squared (R
2) values, with p<0.001 for all results
a 121 subjects with body box measurements;
b 103 subjects with
diffusion capacity measurements;logIN−950= log-transformed emphy-
sema score below -950HU in inspiratory scan; Perc15= emphysema
score as 15
th percentile of attenuation distribution curve in inspiratory
scan; EXP−850= air trapping score below -850HU in expiratory scan;
EXP-850to-910= air trapping score between -850HU and -910HU in
expiratory scan; RVC-860to-950= air trapping score as relative volume
change between -860HU and -950HU; E/I-ratioMLD = expiration to
inspiration ratio of mean lung density
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only the screening trial participants were included, though
the associations were weaker after exclusion of the more
severely affected subjects (Appendix 2).
Multivariate regression analysis
Testing of collinearity and residuals showed a variance
inflation factor below 10 [27] in all models (max: 3.85),
and a normal, homoscedastic distribution of residuals. The
multivariate CT models largely explained the variability in
airflow limitation; R-squared value 0.68 to 0.83 (Table 3).
This pattern did not change when only the screening trial
participants were included, though the explained variance
was lower after exclusion of the more severely affected
subjects; R-squared value 0.49 to 0.59 (Table 3).
Discussion
In a population that covered the range of airflow limitation
from mild to very severe obstruction, we showed that the
combination of quantitative CT measurements of emphy-
sema and air trapping is strongly associated with lung
function impairment, and explains a large proportion of the
variability in airflow limitation.
Previous studies have addressed the small airways
disease component in COPD by quantitative CT, but used
large airway wall dimensions as a surrogate for small
airways disease [28]. Nakano et al reported on the
combination of large airway wall thickening and quantita-
tive emphysema to explain lung function variability and to
detect COPD subgroups. They evaluated 114 smokers, and
showed that quantitative CT measurements of emphysema
and airways wall thickness explained 23% to 49% of lung
function variability [28]. In the present study we found a
higher R-squared value; 68% to 83% for the whole study
population, and 49% to 58% in the screening participants
only. This difference in explained variance compared to the
study of Nakano et al., who found an R-squared of 23% to
49%, is likely due to the fact that air trapping is a more
direct measure of small airways dysfunction compared to
airway wall thickness. Additionally, part of the increase
may be due to differences between the study populations.
Previously, Nakano et al showed that airway wall thicken-
ing in CT closely correlates with small airway dimensions
in histological specimens, and thus can be used as an
indirect sign of small airways disease [5]. Other groups
have shown that the correlation between large airway
measurements and lung function parameters increases with
subsequent airway generations [29–32]. This supports our
view that the signal is strongest in the more peripheral
airways. Additionally, quantification of airway wall dimen-
sions remains technically challenging, especially in the
more distal generations (i.e. beyond the fifth generation).
Therefore, assessment of air trapping with quantitative
Table 3 Results of multivariate linear regression for quantitative CT measurements of emphysema and air trapping and pulmonary function tests
All subjects (N=248) Subanalysis (N=174)
a
CT Model logFEV1 FEV1/FVC logFEV1 FEV1/FVC
logIN−950 +EXP−850 0.81 0.76 0.54 0.58
logIN−950 +EXP-850to-910 0.75 0.72 0.51 0.56
logIN−950 +RVC-860to-950 0.83 0.75 0.53 0.55
logIN−950 +E/I-ratioMLD 0.81 0.76 0.54 0.57
Perc15 +EXP−850 0.81 0.75 0.54 0.55
Perc15 +EXP-850to-910 0.71 0.68 0.49 0.49
Perc15 +RVC-860to-950 0.83 0.75 0.55 0.56
Perc15 +E/I-ratioMLD 0.79 0.73 0.51 0.51
Data given are r-squared (R
2) values
a Lung cancer screening trial participants only, controls to GOLD III; logIN−950= log-transformed emphysema score below -950HU in inspiratory
scan; Perc15= emphysema score as 15
th percentile of attenuation distribution curve in inspiratory scan; EXP−850= air trapping score below -
850HU in expiratory scan; EXP-850to-910= air trapping score between -850HU and -910HU in expiratory scan; RVC-860to-950= air trapping score as
relative volume change between -860HU and -950HU; E/I-ratioMLD = expiration to inspiration ratio of mean lung density
Fig. 1 Graphical illustration of the relationship between quantitative
CT measurements and airflow obstruction (FEV1). The relationship
between the quantitative CT measures and the forced expiratory
volume in one second (FEV1). A log-transformed emphysema score
below -950HU in inspiratory scan (logIN-950) versus FEV1; B
emphysema score as 15th percentile of attenuation distribution curve
in inspiratory scan (Perc15) versus FEV1; C air trapping score below -
850HU in expiratory scan (EXP-850) versus FEV1; D air trapping
score between -850HU and -910HU in expiratory scan (EXP-850 to -
910) versus FEV1; E air trapping score as relative volume change
between -860HUand -950HU (RVC-860 to -950) versus FEV1; F
expiration to inspiration ratio of mean lung density (E/I-ratioMLD)
versus FEV1; GOLD global initiative for chronic obstructive lung
disease

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technical benefits. Although there is an increase in radiation
dose for an additional expiratory CT acquisition, this is
limited; in our screening trial protocol the effective
radiation dose was less than 0.65 mSv for the additional
expiratory CT acquisition.
Previously, the univariate relationship between quantitative
C Tm e a s u r e sa n dl u n gf u n c t i o ni nC O P Di sr e p o r t e di naf e w
studies [23–25, 33, 34]. In these studies, correlation coef-
ficients between E/I-ratioMLD and FEV1 of 0.45 and 0.64 (p<
0.001) are reported, which is lower than what we found.
Reported correlation coefficients with RV/TLC are between
0.54 and 0.71, which is also slightly lower than our results.
These differences may well be due to differences in study
populations, since our study population was larger and
equally covered all the stages of COPD. Further, RVC-860 to
−950 has been previously studied by Matsuoka and colleagues
in a cohort of 36 COPD subjects with GOLD stage 1–4[ 6].
They found correlation coefficients of 0.80 and 0.78 between
this CT air trapping measure and FEV1 and FEV1/FVC,
respectively [6]. Despite the considerably smaller study
population their results are comparable to ours, both for the
whole population, and the less severely affected trial
participants only. Last, the EXP−850 method has been
p u b l i s h e do n l yi na b s t r a c tf o r m a t[ 20], and was previously
used in asthma research for quantification of air trapping [21].
One has to be careful with the conclusion that one
method is better than the other, given the absence of a clear
reference standard for either emphysema or air trapping in
our study. In fact, the main purpose of our study was to
assess how well the quantitative CT measurements can
explain the lung function impairment, instead of testing for
the optimal method. Nevertheless, we feel that air trapping
measurements that combine inspiratory and expiratory CT
data may be preferable when ones purpose is to quantify the
individual disease components in COPD (i.e. emphysema
and small airways disease). This radiologic separation of
disease components may be a next step in further defining
morphologic phenotypes within COPD. The solely expira-
tory measurement of air trapping (i.e. EXP−850) is not
useful for this purpose, because it does not correct for air
that remains in emphysematous spaces on end-expiratory
CT; it thus combines quantification of emphysema and
small airways disease in one measure. Therefore, we
intended to eliminate emphysema from this measurement
by calculating the EXP-850to-910, since Gevenois et al
demonstrated that voxels with a density below -910HU on
expiratory CT represent emphysema [22]. However, the
performance of the models including this measure were
worse, which makes us believe that the air trapping
measurements that combine inspiration and expiration CT
data will outperform the EXP-850to-910 when confronted
with a proper reference standard.
Since only a moderate number of GOLD3 and no GOLD4
subjects were present in the screening trial, we added clinical
subjects with advanced airflow limitation to our study
population. Unfortunately, the inspiratory radiation exposure
and the reconstruction kernel used were not identical in the
clinical and screening subjects. Despite the differences, the
selection of clinical subjects was reasonably the best
achievable option to investigate the total spectrum of COPD.
The use of two different reconstruction filters and a difference
in inspiratory radiation dose may have had some influence on
the quantitative CT measurements [35–38]. However, it has
also been suggested that dose-reduction to as low as 20mAs
can be applied without clinical importance [39–41]. More-
over, after analyzing only the screening trial participants,
examined with a single CT system and protocol, the pattern
of univariate- and multivariate regression analysis remained
the same as in the total population, though was less strong
after exclusion of the 74 more severely affected cases. These
findings support the validity of our conclusions.
Our study has some limitations. First, there is no good
reference standard for air trapping, which is an in vivo
phenomenon. This limitation makes it difficult to prove that
the combined inspiratory-expiratory air trapping measure-
ments are the best methods to quantify air trapping outside
emphysematous spaces. Second, CT data acquisitions were
not spirometrically controlled, which would enable a stan-
dardized inspiration and expiration level. Nevertheless, its
absence strengthens the generalizability of our results since
spirometer-gated CT is not widely applied. Despite these
limitations, the combination of CT emphysema and CT air
trapping explains a large part of the lung function variability.
Third, we acknowledge that spirometry was obtained before
bronchodilator administration, and that some asthma, whether
or not coexisting with COPD, can be present. However, this
likely concerns only a small amount of heavy smoking
subjects. Last, we used a retrospective design and added a
separate patient group due to the paucity of severely
obstructed subjects in the screening group. However, this
was the best achievable option to investigate the total
spectrum of COPD. Moreover, although the explained
variance decreased, the pattern found did not change after
exclusion of the severely affected subjects.
In summary, quantitative CT measures of emphysema and
air trappingare strongly associatedwithairflow limitationina
population that coversthe total range of airflow limitation; the
combination of CT emphysema and air trapping, as simple
densitymeasurementsonpairedinspiratoryandexpiratoryCT
images, explains around three-quarters of the lung function
variabilityinsuchapopulationofCOPDsubjects.Wesuggest
that these measures might gain a role in the identification of
subjects with suspected lung function impairment, based on
radiological data, and might prove useful in phenotyping
COPD. This may be especially interesting in lung cancer
126 Eur Radiol (2012) 22:120–128screening, where large numbers of examinations are obtained
in heavy smokers.
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Appendix 1
To score lung segmentation the observer was able to scroll
through the entire scan with a semi-translucent colour
overlay of the segmentation. This overlay could be
removed and replaced at any time. The guidelines for
scoring, as provided to the observers, was as follows:
Excellent: over 95% of the segmentation is correct
Minor errors: 80-95% of the segmentation is correct
Major errors: 50-80% of the segmentation is correct
Totally wrong: less than 50% of the segmentation is
correct
Appendix 2
References
1. Global Initiative for Chronic Obstructive Pulmonary Disease.
Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease (2009) Available at http://
www.goldcopd.com. Accessed March 2011
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001)
Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease. NHLBI/WHO Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) Workshop
summary. Am J Respir Crit Care Med 163:1256–1276
3. Hogg JC (2004) Pathophysiology of airflow limitation in chronic
obstructive pulmonary disease. Lancet 364:709–721
4. Muller NL, Staples CA, Miller RR, Abboud RT (1988) “Density
mask”. An objective method to quantitate emphysema using
computed tomography. Chest 94:782–787
5. Nakano Y, Wong JC, de Jong PA, Buzatu L, Nagao T, Coxson HO,
Elliott WM, Hogg JC, Pare PD (2005) The prediction of small
airway dimensions using computed tomography. Am J Respir Crit
Care Med 171:142–146
6. Matsuoka S, Kurihara Y, Yagihashi K, Hoshino M, Watanabe N,
Nakajima Y (2008) Quantitative assessment of air trapping in
chronic obstructive pulmonary disease using inspiratory and
expiratory volumetric MDCT. AJR Am J Roentgenol 190:762–
769
7. Reilly JJ (2008) COPD and declining FEV1–time to divide and
conquer? N Engl J Med 359:1616–1618
8. Rennard SI, Vestbo J (2008) The many "small COPDs": COPD
should be an orphan disease. Chest 134:623–627
9. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL,
Fabbri LM, Goldin JG, Jones PW, MacNee W, Make BJ, Rabe KF,
Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR,
Wouters EF, Martinez FJ (2010) Chronic obstructive pulmonary
disease phenotypes: the future of COPD. Am J Respir Crit Care
Med 182:598–604
10. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD,
Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK,
Tal-Singer R, Wouters E, Yates JC, Vestbo J (2010) Character-
isation of COPD heterogeneity in the ECLIPSE cohort. Respir
Res 11:122
11. Hoop BJ, Mohamed Hoesein F, Zanen P, Gietema HA, van
Ginneken B, Isgum I, Mol C, van Klaveren R, Dijkstra A, Boezen
H, Groen H, Postma D, Lammers JW, Prokop M (2011) CT-
quantified emphysema in heavy smokers: predictive value for rate
of lung function decline. Thorax. doi:10.1136/thx.2010.145995
12. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET,
Nackaerts K, Prokop M, Habbema JD, Oudkerk M, van Klaveren
RJ (2007) Risk-based selection from the general population in a
screening trial: selection criteria, recruitment and power for the
Dutch-Belgian randomised lung cancer multi-slice CT screening
trial (NELSON). Int J Cancer 120:868–874
13. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,
Yernault JC (1993) Lung volumes and forced ventilatory flows.
Report Working Party Standardization of Lung Function Tests,
European Community for Steel and Coal. Official Statement of
the European Respiratory Society. Eur Respir J Suppl 16:5–40
14. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi
R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen
R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF,
Pellegrino R, Viegi G, Wanger J (2005) General considerations for
lung function testing. Eur Respir J 26:153–161
15. van Rikxoort EM, de Hoop B, Viergever MA, Prokop M, van
Ginneken B (2009) Automatic lung segmentation from thoracic
computed tomography scans using a hybrid approach with error
detection. Med Phys 36:2934–2947
Table 4 Results of univariate linear regression analysis for quantita-
tive CT emphysema and air trapping measurements and pulmonary
function tests in a subset of 174 subjects
a
logFEV1 FEV1/FVC RV/TLC
b Kco
c
CT emphysema
logIN-950 0.25
* 0.46
* 0.07
‡ 0.25
*
Perc15 0.14
* 0.35
* 0.03
NS 0.16
*
CT air trapping
EX-850 0.41
* 0.54
* 0.24
* 0.15
*
EX-850to-910 0.36
* 0.44
* 0.24
* 0.11
†
RVC-860to-950 0.28
* 0.21
* 0.08
‡ 0.01
NS
E/I-ratioMLD 0.34
* 0.34
* 0.27
* 0.09
†
Data given are r-squared (R
2) values
aLung cancer screening trial participants only, controls to GOLD3;
b
71 subjects with body box measurements;
c 70 subjects with diffusion
capacity measurements
*p<0.001;
† p<0.01;
‡ p<0.05;
NS not significant; logIN-950 = log-
transformed emphysema score below -950HU in inspiratory scan;
Perc15 = emphysema score as 15th percentile of attenuation
distribution curve in inspiratory scan; EXP-850 = air trapping score
below -850HU in expiratory scan; EXP-850to-910 = air trapping score
between -850HU and -910HU in expiratory scan; RVC-860to-950 = air
trapping score as relative volume change between -860HU and -
950HU; E/I-ratioMLD = expiration to inspiration ratio of mean lung
density
Eur Radiol (2012) 22:120–128 12716. Schilham AM, van Ginneken B, Gietema H, Prokop M (2006)
Local noise weighted filtering for emphysema scoring of low-dose
CT images. IEEE Trans Med Imaging 25:451–463
17. Gevenois PA, De Maertelaer V, De Vuyst P, Zanen J, Yernault JC
(1995) Comparison of computed density and macroscopic
morphometry in pulmonary emphysema. Am J Respir Crit Care
Med 152:653–657
18. Gevenois PA, De Vuyst P, De Maertelaer V, Zanen J, Jacobovitz D,
Cosio MG, Yernault JC (1996) Comparison of computed density
and microscopic morphometry in pulmonary emphysema. Am J
Respir Crit Care Med 154:187–192
19. Newell JD Jr, Hogg JC, Snider GL (2004) Report of a workshop:
quantitative computed tomography scanning in longitudinal
studies of emphysema. Eur Respir J 23:769–775
20. van Ginneken B, Murphy K, van Rikxoort EM, Isgum I, de Hoop B,
Prokop M, de Jong PA, Gietema HA (2009) Quantification of
Emphysema and Small Airway Disease in COPD Patients from
Lobar Analysis of Volumetric Inspiration and Expiration Thoracic CT
Scans. Radiological Society of North America, 95th Annual Meeting
21. Busacker A, Newell JD Jr, Keefe T, Hoffman EA, Granroth JC,
Castro M, Fain S, Wenzel S (2009) A multivariate analysis of risk
factors for the air-trapping asthmatic phenotype as measured by
quantitative CT analysis. Chest 135:48–56
22. Gevenois PA, De Vuyst P, Sy M, Scillia P, Chaminade L, de
Maertelaer V, Zanen J, Yernault JC (1996) Pulmonary emphysema:
quantitative CT during expiration. Radiology 199:825–829
23. Kubo K, Eda S, Yamamoto H, Fujimoto K, Matsuzawa Y,
Maruyama Y, Hasegawa M, Sone S, Sakai F (1999) Expiratory
and inspiratory chest computed tomography and pulmonary
function tests in cigarette smokers. Eur Respir J 13:252–256
24. Eda S, Kubo K, Fujimoto K, Matsuzawa Y, Sekiguchi M, Sakai F
(1997) The relations between expiratory chest CT using helical
CT and pulmonary function tests in emphysema. Am J Respir Crit
Care Med 155:1290–1294
25. O'Donnell RA, Peebles C, Ward JA, Daraker A, Angco G,
Broberg P, Pierrou S, Lund J, Holgate ST, Davies DE, Delany DJ,
Wilson SJ, Djukanovic R (2004) Relationship between peripheral
airway dysfunction, airway obstruction, and neutrophilic inflam-
mation in COPD. Thorax 59:837–842
26. Goedhart DM, Zanen P (2002) Selecting the best method to
evaluate bronchodilation when analysing bronchodilator studies.
Stat Med 21:3677–3685
27. Fox J (1991) Regression diagnostics. Sage Publications, Thousand
Oak
28. Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M,
Nishimura K, Itoh H, Pare PD, Hogg JC, Mishima M (2000)
Computed tomographic measurements of airway dimensions and
emphysema in smokers. Correlation with lung function. Am J
Respir Crit Care Med 162:1102–1108
29. Achenbach T, Weinheimer O, BiedermannA, SchmittS, Freudenstein
D, Goutham E, Kunz RP, Buhl R, Dueber C, Heussel CP (2008)
MDCTassessment of airway wall thickness in COPD patients using a
new method: correlations with pulmonary function tests. Eur Radiol
18:2731–2738
30. Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S,
Ito Y, Betsuyaku T, Nishimura M (2006) Airflow limitation and
airway dimensions in chronic obstructive pulmonary disease. Am
J Respir Crit Care Med 173:1309–1315
31. Matsuoka S, Kurihara Y, Yagihashi K, Hoshino M, Nakajima Y
(2008) Airway dimensions at inspiratory and expiratory multi-
section CT in chronic obstructive pulmonary disease: correlation
with airflow limitation. Radiology 248:1042–1049
32. Yamashiro T, Matsuoka S, Estepar RS, Dransfield MT, Diaz A,
Reilly JJ, Patz S, Murayama S, Silverman EK, Hatabu H, Washko
GR, Quantitative assessment of bronchial wall attenuation with
thin-section CT (2010) An indicator of airflow limitation in
chronic obstructive pulmonary disease. AJR Am J Roentgenol
19:363–369
33. Lee YK, Oh YM, Lee JH, Kim EK, Lee JH, Kim N, Seo JB, Lee
SD (2008) Quantitative assessment of emphysema, air trapping,
and airway thickening on computed tomography. Lung 186:157–
165
34. Yamashiro T, Matsuoka S, Bartholmai BJ, San Jose ER, Ross JC,
Diaz A, Murayama S, Silverman EK, Hatabu H, Washko GR
(2010) Collapsibility of lung volume by paired inspiratory and
expiratory CT scans: correlations with lung function and mean
lung density. Acad Radiol 17:489–495
35. Gierada DS, Bierhals AJ, Choong CK, Bartel ST, Ritter JH, Das
NA, Hong C, Pilgram TK, Bae KT, Whiting BR, Woods JC, Hogg
JC, Lutey BA, Battafarano RJ, Cooper JD, Meyers BF, Patterson
GA (2010) Effects of CT section thickness and reconstruction
kernel on emphysema quantification relationship to the magnitude
of the CT emphysema index. Acad Radiol 17:146–156
36. Ley-Zaporozhan J, Ley S, Weinheimer O, Iliyushenko S, Erdugan
S, Eberhardt R, Fuxa A, Mews J, Kauczor HU (2008) Quantitative
analysis of emphysema in 3D using MDCT: influence of different
reconstruction algorithms. Eur J Radiol 65:228–234
37. Boedeker KL, Nitt-Gray MF, Rogers SR, Truong DA, Brown MS,
Gjertson DW, Goldin JG (2004) Emphysema: effect of recon-
struction algorithm on CT imaging measures. Radiology 232:295–
301
38. Yuan R, Mayo JR, Hogg JC, Pare PD, McWilliams AM, Lam S,
Coxson HO (2007) The effects of radiation dose and CT
manufacturer on measurements of lung densitometry. Chest
132:617–623
39. Madani A, De Maertelaer V, Zanen J, Gevenois PA (2007)
Pulmonary emphysema: radiation dose and section thickness at
multidetector CT quantification–comparison with macroscopic
and microscopic morphometry. Radiology 243:250–257
40. Gierada DS, Pilgram TK, Whiting BR, Hong C, Bierhals AJ, Kim
JH, Bae KT (2007) Comparison of standard- and low-radiation-
dose CT for quantification of emphysema. AJR Am J Roentgenol
188:42–47
41. Zaporozhan J, Ley S, Weinheimer O, Eberhardt R, Tsakiris I,
Noshi Y, Herth F, Kauczor HU (2006) Multi-detector CT of the
chest: influence of dose onto quantitative evaluation of severe
emphysema: a simulation study. J Comput Assist Tomogr 30:460–
468
128 Eur Radiol (2012) 22:120–128